LCLAT1 and ependymoblastoma: We identified lysocardiolipin acyltransferase 1 (LCLAT1, also known as ALCAT1, LYCAT, or AGPAT8), the CL acyl chain remodeling enzyme, as a potential new therapeutic target in ETMR, and we demonstrate efficacy in targeting LCLAT1-driven CL remodeling and the mitochondrial phenotype detected.